Targeting tau in addition to amyloid-β could be the next phase of disease modification in Alzheimer’s disease. The TANGO trial of gosuranemab, which binds the tau N terminus, affected neither clinical outcomes nor brain levels of aggregated tau. The results highlight the importance and challenge of reducing aggregated tau.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Shulman, M. et al. Nat. Aging https://doi.org/10.1038/s43587-023-00523-w (2023).
van Dyck, C. H. et al. N. Engl. J. Med. 388, 9–21 (2022).
Sims, J. R. et al. J. Am. Med. Assoc. 330, 512–527 (2023).
Serrano-Pozo, A., Frosch, M. P., Masliah, E. & Hyman, B. T. Cold Spring Harb. Perspect. Med. 1, a006189 (2011).
Sato, C. et al. Neuron 97, 1284–1298.e7 (2018).
Mengel, D. et al. Ann. Neurol. 88, 878–892 (2020).
Monteiro, C. et al. Neurology 101, e1391–e1401 (2023).
Florian, H. et al. Brain 146, 2275–2284 (2023).
Doody, R. S. et al. N. Engl. J. Med. 370, 311–321 (2014).
Sperling, R. A. et al. N. Engl. J. Med. 389, 1096–1077 (2023).
Mummery, C. J. et al. Nat. Med. 29, 1437–1447 (2023).
Fitzpatrick, A. W. P. et al. Nature 547, 185–190 (2017).
Horie, K. et al. Nat. Med. 29, 1954–1963 (2023).
Ossenkoppele, R. et al. Nat. Med. 28, 2381–2387 (2022).
Therriault, J. et al. Nat. Aging 2, 526–535 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.M.S. receives research support from the following grants: K08 NS128329 and the Alzheimer’s Association. R.A.S. has served as a paid consultant for AC Immune, Alector, Acumen, Bristol Myers Squibb, Genentech, NervGen, Oligomerix, Prothena, Renew, Vigil Neuroscience, Ionis and Vaxxinity. She receives research support from Eisai and Eli Lilly as part of public–private partnership clinical trials, and also receives research support from the following grants: P01 AG036694, U24 AG057437, R01 AG063689, R01 AG054029, R01 AG053798, GHR Foundation, National Institute on Aging, Fidelity Biosciences, and the Alzheimer’s Association.
Rights and permissions
About this article
Cite this article
Stern, A.M., Sperling, R.A. Tangles, not TANGO: targeting tau aggregates. Nat Aging 3, 1472–1473 (2023). https://doi.org/10.1038/s43587-023-00526-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43587-023-00526-7
